Document is current
Any future updates will be listed below
-
Authors
Kovácsházi, Csenger
Hambalkó, Szabolcs
Sayour, Nabil V.
Gergely, Tamás G.
Brenner, Gábor B.
Pelyhe, Csilla
Kapui, Dóra
Weber, Bennet Y.
Hültenschmidt, Alexander L.
Pállinger, Éva
Buzás, Edit I.
Zolcsák, Ádám
Kiss, Bálint
Bozó, Tamás
Csányi, Csilla
Kósa, Nikolett
Kellermayer, Miklós
Farkas, Róbert
Karvaly, Gellért B.
Wynne, Kieran
Matallanas, David
Ferdinandy, Péter
Giricz, Zoltán
-
Funding
Funding for this research was provided by:
Magyarország Kormánya (EFOP-3.6.3-VEKOP-16-2017-00009)
Richter Gedeon Talentum Alapítvány,Hungary
Science Foundation Ireland (18/RI/5702)
Nemzeti Kutatási és Technológiai Hivatal (K139105)
Semmelweis University
- License Information
-
More Information
Article History
Received: 7 September 2023
Accepted: 20 May 2024
First Online: 26 May 2024
Competing interests
: PF is the founder and CEO, and ZG is the Translational Program Director of Pharmahungary Group, a group of R&D companies. EIB is member of the Advisory Board of Sphere Gene Therapeutics Inc. (Boston, MA, USA) and the Scientific Advisory Board of ReNeuron (UK). All other authors declare no competing interests.
